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Available online 09 May 2016Objective:GH treatment (GHT) can lead to glucosemetabolism impairment through decreased insulin sensitivity
and impaired pancreatic β-cell function, which are the two key components of the pathogenesis of diabetes.
Therefore, in addition to insulin sensitivity, during GHT it is very important to perform a reliable evaluation of in-
sulin secretion. However, conﬂicting data exist regarding the insulin secretion in children during GHT. C-peptide
provides amore reliable estimate ofβ-cell function than insulin, but few studies evaluated it during GHT.Our aim
was to assess the usefulness of C-peptide in the evaluation of insulin secretion in GH deﬁciency (GHD) children.
Design: In 48 GHD children, at baseline and after 12 and 24 months of GHT, and in 56 healthy subjects we eval-
uated fasting and glucagon-stimulated (AUCCpep) C-peptide levels in addition to other commonly used secretion
indexes, such as fasting and oral glucose tolerance test-stimulated insulin levels (AUCINS), Homa-β, and
insulinogenic index. The main outcomes were the change in C-peptide during GHT and its correlation with the
auxological and hormonal parameters.
Results:At baseline GHD children showed a signiﬁcant lower AUCCpep (p=0.006), while no differencewas found
for the other indexes. Both fasting C-peptide (beta 0.307, p = 0.016) and AUCCpep (beta 0.379, p = 0.002) were
independently correlatedwith IGF-I SDS,while no correlationwas found for all other indexes. After 12months an
increase inHoma-β (pb 0.001), fasting C-peptide (p=0.002) andAUCCpep (p b 0.001)was found. Atmultivariate
analysis, only fasting C-peptide (beta 0.783, p= 0.001) and AUCCpep (beta 0.880, p b 0.001) were independently
correlated with IGF-I SDS.
Conclusions: C-peptide, rather than the insulin-derived indexes, has proved to be themost useful marker of insu-
lin secretion correlated to IGF-I levels in GHD children. Therefore, we suggest the use of glucagon test both as di-
agnostic test for the GH assessment and as a useful tool for the evaluation of insulin secretion during GHT in
children.
© 2016 Elsevier Ltd. All rights reserved.Keywords:
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Growth hormone (GH) is known to play a signiﬁcant metabolic role
[1]. Untreated GH deﬁciency (GHD) in children, as well as in adults, is
associated with abnormalities in body composition with increased vis-
ceral fat, dyslipidemia, increased peripheral inﬂammatory markers
and cardiovascular risk [2–4]. In addition, GHD is often associated
with impaired glucose metabolism and the increased prevalence of
type 2 diabetes is likely due to the decreased insulin sensitivity and to
the inadequate β-cell ability to counteract the insulin resistance [5,6].
Moreover, GH has an insulin antagonist effect [7,8] in addition tormone treatment; GHD, growth
.directly stimulate β-cell mass and insulin secretion [9–11] and these ef-
fects can induce important changes in glucose metabolism, leading to
affect both insulin sensitivity and secretion [12]. In in vivo studies, a re-
duction in insulin sensitivity,mainly correlatedwith an increase in insu-
lin levels, has been widely demonstrated in children during GH
treatment (GHT) [13]. Patients who develop insulin resistance during
GHT can represent a population at risk for diabetes and monitoring of
glucose and insulin metabolism during GHT has been recommended
[14,15]. Given that both the decreased insulin sensitivity and the im-
paired β-cell function are two key components of the pathogenesis of
type 2 diabetes, it is very important to perform a reliable evaluation of
insulin secretion in subjects potentially at risk of glucose metabolism
impairment, as in children during GHT. In addition, a mutual relation-
ship between insulin secretion and GH/IGF-I axis is well established in
healthy subjects, as well as in diabetic patients [16,17], so it is interest-
ing to examinewhether this relationship is maintained in GHD children
during GHT.
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evaluate the change in insulin secretion during GHT, but with discor-
dant results. The evaluation of β-cell function based on fasting parame-
ters has not always proved to be a reliablemeasure and the existingdata
about the effect of GHT on insulin secretion are controversial. Indeed,
both an increase [18] and a decrease in insulin secretion, in terms of in-
adequate adaptation of insulin secretion when the insulin sensitivity
deteriorates [19,20], have been demonstrated. We already showed in
children during GHT a worsening of the oral disposition index, which
declines before the glucose levels rise into the diabetic range [6].
Given these discrepancies, in our hypothesis amore accurate estimation
of the effect of GH on β-cell functionmay come by analyzing the C-pep-
tide secretion. It is known that C-peptide provides a more reliable esti-
mate of β-cell function in healthy children and it better correlates
with the gold standard hyperglycemic clamp than insulin levels [21].
However, very few studies have evaluated the C-peptide levels in chil-
dren during GHT [18,22].
The aim of this study was to assess the reliability of both fasting and
stimulated C-peptide in the evaluation of insulin secretion and its corre-
lation with the auxological and hormonal parameters in GHD children
during GHT.
2. Materials and methods
Weprospectively evaluated 48 children (32M, 16 F;mean age 9.8±
2.1 years; range 3.7–12.9) affected by isolated idiopathic GHD consecu-
tively admitted to the Section of Endocrinology of the University of Pa-
lermo during the years 2012–2013. Fifty-six healthy subjects, matched
for sex (39M, 17 F), age (mean age 10.2±1.3 years; range 5.1–12), stat-
ure and pubertal status, were recruited as a control group at baseline
among children referred for short stature. In this group of children the
screening for short stature did not reveal endocrine alterations and
GHD was excluded by GH peak N10 μg/l after two stimuli.
We excluded children affected by multiple pituitary hormone deﬁ-
ciency or receiving other hormonal replacement treatment. All children,
even the older ones, were in the ﬁrst or second stage of sexual develop-
ment according to the criteria of Marshall and Tanner [23] to avoid any
interference of puberty on themetabolic parameters analyzed, and they
maintained the prepubertal hormonal status during the observation pe-
riod (i.e. FSH and LH b1 mU/ml, total testosterone and 17β-Estradiol
b0.50 ng/ml and b5 pg/ml in males and females, respectively).
The diagnosis of GHDwas established by the clinical, auxological, ra-
diological and biochemical criteria of the GH Research Society [24]. As
auxological data we considered height and growth velocity 1 year be-
fore the diagnosis. Clinical and auxological criteria included height N2
standard deviations (SD) below the mean and a growth velocity over
1 year N1 SD below the mean for age, or a decrease in height SD of
N0.5 over 1 year or, without severe short stature, a growth velocity N2
SD below the mean over 1 year or, ﬁnally, height N1.5 SD below the
midparental height.
As radiological criteria we considered a bone age delay, estimated
from an x-ray of the left wrist and hand and evaluated according to
methods of Greulich and Pyle, of at least 1 yearwith respect to the chro-
nological age [25]. Biochemically GHDwas demonstrated by the failure
of GH to respond to two stimuli, with GH peaks below 10 μg/l. Neuroim-
aging, with magnetic resonance of the hypothalamic-pituitary region,
was performed in GHD children with more severe GHD, i.e. with GH
peak ≤3 μg/l (No. 23 children). Among them, 4 patients showed a pitu-
itary hypoplasia and 3 a partial empty sella.
All patients enrolled were treated with GH for at least 24 months.
The patients received GH once daily at bedtimewith a pen injection sys-
tem. Insulin-like growth factor (IGF)-I levels and the growth velocity
have allowed us to determine theGH dose. Speciﬁcally, themain targets
were arbitrarily IGF-I levels between 0.5 and 1.5 SDS and growth
velocity N 0.5 SDS. The initial daily dose of GH was 0.025 mg/kg and it
has been gradually increased by 0.002–0.003mg/kg/day every 6months(mean daily dose of 0.028 mg/kg from months 6 to 12; 0.031 mg/kg
from months 12 to 18; 0.033 mg/kg from months 18 to 24).
2.1. Study protocol
In all children, at baseline, GH secretion was assessed by arginine
and glucagon (GST) stimulation test, performed in two different days.
During arginine test, blood samples were obtained at 0, 30, 60, 90,
120 min after the administration of the stimulus (arginine
monohydrochloride: 0.5 g/kg up to 30 g. given intravenously over
30 min) for GH measurements. During GST, blood samples were
collected at 0, 30, 60, 90, 120, 150, 180 and 240 min after the injection
of 30 μg/kg (up to 1.000 μg) intramuscularly of glucagon (GlucaGen,
NovoNordisk, Bagsvaerd, Denmark), for the measurements of both GH
as diagnostic tool for the GHD [26,27] and C-peptide concentrations as
estimate of insulin secretion. The area under the curve (AUC) of C-pep-
tide (AUCCpep) during GST was also calculated using the trapezoidal
rule.
In a different day, a blood sample was drawn after an overnight fast
for the measurement of Hemoglobin A1c (HbA1c), plasma glucose, in-
sulin and IGF-I concentrations. This sample also served as the baseline
sample for an oral glucose tolerance test (OGTT). Blood samples were
collected every 30 min for 2 h for glucose and insulin measurements.
AUC of glucose (AUCGLU) and insulin (AUCINS) during OGTT was calcu-
lated using the trapezoidal rule.
After the diagnosis of GHDwasmade, in GHD children in addition to
the height, bodymass index (BMI) andwaist circumference (WC)mea-
surements, we performed bothOGTT andGST after 12 and 24months of
GHT. Height, BMI, WC and IGF-I were expressed as SD score (SDS) due
to the wide age range of patients.
The estimation of the basal insulin secretion included fasting insulin
levels and the homeostasis model assessment for β-cell function
(Homa-β) index [28]. The early insulin-secretion rate was evaluated
using the insulinogenic index [29], while the stimulated total insulin se-
cretion was evaluated by AUCINS. In addition, an estimate of the endog-
enous insulin secretion was obtained from C-peptide and AUCCpep.
As surrogate estimates of insulin sensitivity we considered the ho-
meostasis model assessment estimate of insulin resistance (Homa-IR)
[28], the quantitative insulin sensitivity check index (QUICKI) [30] and
the insulin sensitivity index (ISI), a composite index derived from the
OGTT and validated by Matsuda and DeFronzo [31]. In the control sub-
jects, these evaluations were performed only at baseline.
The institutional Ethics Committee of the University of Palermo ap-
proved this study. At the time of hospitalization, an informed consent
for the scientiﬁc use of the data was obtained from both the participants
and their parents.
2.2. Hormone and biochemical assays
All biochemical data were collected after overnight fasting. Glucose
and HbA1c were measured in the centralized accredited laboratories
with standardmethods. Serum insulin wasmeasured by ELISA (DRG In-
struments GmbH, Germany). The sensitivity of themethodwas 1 IU/ml.
The normal insulin range (IU/ml)was 5–19. SerumGH levelsweremea-
sured by immunoradiometric assay using commercially available kits
(Radim, Italy). The sensitivity of the assay was 0.04 µg/l. The intra and
inter-assay coefﬁcients of variation (CV) were 2.5–3.9 and 3.8–5.0%, re-
spectively. We reported GH concentrations in μg/l of IS 98/574. Serum
total IGF-I was assayed in the same laboratory with the ELISA method
(OCTEIA IGF-I kit, IDS Inc., Fountain Hills, AZ, USA). The sensitivity of
the method was 1.9 μg/l. The inter- and intra-assay CV values were 7–
7.1 and 2.3–3.5% respectively, at IGF-I levels of 90.7–186 and 66.7–
120.9 μg/l respectively. The normal ranges (males and females com-
bined) of total IGF-I levels (μg/l) were: 12–108 (0–1 years); 13–100
(1–3 years); 26–280 (3–6 years); 85–230 (6–9 years); 98–404 (9–
12 years); 142–525 (12–15 years); 146–415 (15–20 years). Values
Table 1
Clinical and biochemical features of GHD children at diagnosis (baseline) and control sub-
jects. Data are presented as rates and proportions for the categorical data and as mean ±
standard deviation (SD), mean ± standard deviation score (SDS, when indicated) or
median ± interquartile range (IR) for the continuous variables, when appropriate.
Control group GHD at baseline p*
(N. 56) (N. 48)
Gender 235
Males 39 (70%) 32 (67%)
Females 17 (30%) 16 (33%)
Age (years) 10.2 ± 1.3 9.8 ± 2.1 0.113
Height (SDS) −2.1 ± 0.6 −2.2 ± 0.9 0.423
Height in comparison to the
midparental height (SDS)
−0.82 ± 0.11 −1.90 ± 0.10 b0.001
Growth velocity (cm/year) 4.2 ± 0.5 3.2 ± 0.5 b0.001
Growth velocity (SDS) −1.7 ± 0.6 −2.5 ± 0.6 b0.001
BMI (kg/m2) 16.4
(11.9–26.8)
17.2
(12.5–23.1)
0.468
BMI (SDS) −0.6
(−1.5–2.1)
−0.4
(−1.4–1.5)
0.463
WC (SDS) 0.16
(−1.61–1.39)
−0.27
(−2.50–1.94)
0.085
IGF-I (SDS) 0.74 ± 0.39 −1.55 ± 0.66 b0.001
GH peak after arginine
test (μg/l)
11.3
(3.2–22.1)
3.5 (0.07–7.8) b0.001
GH peak after GST (μg/l) 12.8
(3.9–43.3)
5.6 (0.12–8.4) b0.001
Glucose metabolism
Fasting glucose (mmol/l) 4.2 ± 0.5 4.2 ± 0.6 0.847
AUCGLU (mmol/l) 750
(593–1064)
734
(472–1297)
0.793
HbA1c (%) 5.2 ± 0.3 5.2 ± 0.3 0.777
Insulin secretion indexes
Fasting insulin (IU/ml) 3.2 (0.2–8.8) 2.8 (0.2–8.7) 0.743
AUCINS (IU/ml) 4303
(789–9693)
3397
(528–12,973)
0.052
Homa-β 12.3
(0.5–38.7)
9.7 (2.5–49.1) 0.464
Insulinogenic index 0.7 (0–2.6) 0.6 (0–3.0) 0.096
Fasting C-peptide (ng/ml) 1.5 ± 0.5 1.3 ± 0.6 0.166
AUCCpep (ng/ml) 537 ± 225 436 ± 231 0.006
Insulin sensitivity indexes
Homa-IR 0.59
(0.03–1.63)
0.53
(0.03–2.69)
0.814
QUICKI 0.45 ± 0.12 0.45 ± 0.10 0.793
ISI-Matsuda 12.1
(4.6–38.4)
14.5 (2.0–34.7) 0.457
AUC: area under the curve; OGTT: oral glucose tolerance test; GST: glucagon stimulation
test.
AUCINS: AUC of insulin during OGTT; AUCCpep: AUC of C-peptide during GST.
p* value corrected for age and pubertal status.
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the manufacturer. Serum C-peptide was measured by electrochemi-
luminescence immunoassay method (Roche Diagnostics Deutschland
GmbH). The sensitivity of the method was 0.01 ng/ml. The normal
range (ng/ml) was 0.010–40.0.
2.3. Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17 was used
for data analysis. Baseline characteristics were presented as mean± SD
or as median values ± interquartile range (IR) for continuous variables,
when appropriate. Normality of distribution for the quantitative vari-
ables was assessed with the Kolmogorov-Smirnov test. The differences
between groups were evaluated with the t-test if with normal distribu-
tion or with Mann–Whitney test (non-parametric test) if without nor-
mal distribution. All differences in auxological and metabolic
parameters and all correlations among variables were corrected for
age and pubertal status through a logistic regression model. The
Pearson's correlation was performed among continuous variables with
normal distribution, while the correlations among continuous variables
without normal distribution were determined by using the Spearman's
test (non-parametric equivalent for Pearson test). To evaluate the inde-
pendent variables inﬂuencing C-peptide levels, a linear regression
model was performed. A p value b0.05 was considered statistically
signiﬁcant.
3. Results
The clinical and biochemical features of control subjects, GHD chil-
dren at diagnosis and after 12 and 24 months of GHT are shown in
Table 1 and Table 2.
3.1. Clinical and hormonal parameters
No signiﬁcant difference in height, BMI and WC between GHD chil-
dren at baseline and control subjects was found (Table 1). Conversely,
as expected, GHD children at baseline showed signiﬁcantly lower
growth velocity SD (−2.5 ± 0.6 vs.−1.7 ± 0.6; p b 0.001), IGF-I SDS
(−1.55 ± 0.76 vs. 0.74 ± 0.39; p b 0.001), GH peak after arginine
(3.7 ± 2.7 vs. 11.8 ± 5.6 μg/l; p b 0.001) and GST (5.8 ± 4.9 vs.
16.5 ± 8.7 μg/l; p b 0.001) than controls.
In theGHDgroup, the growth signiﬁcantly increased after 12months
of GHT (height SDS:−1.8 ± 0.6 vs.−2.2 ± 0.9; p b 0.001; growth ve-
locity SD: 1.6 ± 0.8 vs.−2.5 ± 0.6; p b 0.001), with a concomitant sig-
niﬁcant increase in WC SDS [0.01 (−1.63–2.22) vs. −0.27 (−2.50–
1.94); p = 0.002] and IGF-I SDS (1.24 ± 0.84 vs. −1.55 ± 0.76;
p b 0.001) andwith a subsequent stability or a slight and not statistically
signiﬁcant increase, after 24 months (Table 2).
3.2. Glucose metabolism and insulin sensitivity indexes
All GHD children at baseline showed a normal glucose tolerance
with normal fasting glucose (4.2 ± 0.6 mmol/l), insulin [2.8 (0.2–8.7)
IU/ml] and HbA1c (5.2 ± 0.3%) levels, without signiﬁcant difference of
these parameters compared to the control subjects. Similarly, no differ-
ence was found in AUCGLU, Homa-IR, QUICKI and ISI Matsuda between
GHD children at baseline and control subjects (Table 1).
After 12months of GHT, despite all children remainedwith a normal
glucose tolerance, a signiﬁcant increase in fasting glucose (4.6 ± 0.5 vs.
4.2 ± 0.6 mmol/l; p = 0.003), fasting insulin [8 (0.2–26.7) vs. 2.8 (0.2–
8.7) IU/ml; p b 0.001] and Homa-IR [(1.7 (0–5.8) vs. 0.53 (0.03–2.69);
p b 0.001], with a signiﬁcant decrease in QUICKI (0.37 ± 0.08 vs.
0.45 ± 0.10; p = 0.003) and ISI Matsuda [(5.7 (2.1–30.9) vs. 14.5
(2.0–34.7); p b 0.001] was found, without signiﬁcant change in AUCGLU
and Hba1c levels. These trends were maintained after 24 months of
treatment, although not statistically signiﬁcant (Table 2).3.3. Insulin secretion indexes
At baseline, no signiﬁcant difference was found in Homa-β,
insulinogenic index and AUCINS between GHD children and control sub-
jects, while GHD children showed signiﬁcant lower AUCCpep during GST
(436 ± 231 vs. 537 ± 225 ng/ml; p = 0.006) and lower fasting C-pep-
tide, although non statistically signiﬁcant (Table 1). A signiﬁcant posi-
tive correlation of both fasting C-peptide and AUCCpep with IGF-I SDS
(p = 0.007 and p b 0.001, respectively), height SDS (both p b 0.001),
BMI SDS (both p b 0.001) and WC SDS (both p b 0.001) was found at
baseline. Similarly, the other indexes of insulin secretion (fasting insu-
lin, AUCINS, Homa-β), with the exception of insulinogenic index, were
signiﬁcantly correlated with the clinical and hormonal parameters
(Table 3). At multivariate analysis, both fasting C-peptide (beta 0.307,
p = 0.016) and AUCCpep (beta 0.379, p = 0.002) independently
Table 2
Clinical and biochemical features of GHD children at diagnosis (baseline) and after 12 and 24 months of GH treatment. Data are presented as mean ± standard deviation (SD), mean ±
standard deviation score (SDS, when indicated) or median ± interquartile range (IR) for the continuous variables, when appropriate.
Baseline 12 months 24 months p p*
Height (SDS) −2.2 ± 0.9 −1.8 ± 0.6 −1.3 ± 0.6 b0.001 0.077
Growth velocity (cm/year) 3.2 ± 0.5 8.5 ± 2.4 7.9 ± 2.1 b0.001 0.572
Growth velocity (SDS) −2.5 ± 0.6 1.6 ± 0.8 1.4 ± 0.3 b0.001 0.665
BMI (kg/m2) 17.2 (12.5–23.1) 17 (12.7–27.2) 18 (14.3–24) 0.081 0.051
BMI (SDS) −0.4 (−1.4–1.5) −0.3 (−1.3–1.8) 0.01 (−1.3–1.3) 0.106 0.058
WC (SDS) −0.27 (−2.50–1.94) 0.01 (−1.63–2.22) 0.05 (−1.14–2.06) 0.002 0.859
IGF-I (SDS) −1.55 ± 0.66 1.14 ± 0.44 1.29 ± 0.31 b0.001 0.113
Glucose metabolism
Fasting glucose (mmol/l) 4.2 ± 0.6 4.6 ± 0.5 4.7 ± 0.5 0.003 0.883
AUCGLU (mmol/l) 734 (472–1297) 745 (531–1261) 679 (526–858) 0.414 0.929
HbA1c (%) 5.2 ± 0.3 5.3 ± 3.1 5.2 ± 0.4 0.053 0.907
Insulin secretion indexes
Fasting insulin (IU/ml) 2.8 (0.2–8.7) 8 (0.2–26.7) 9.5 (0.3–25.3) b0.001 1
AUCINS (IU/ml) 3397 (528–12,973) 5043 (592–20,506) 5386 (2224–10,477) 0.213 0.959
Homa-β 9.7 (2.5–49.1) 28.8 (1.6–76.6) 35.2 (2.2–76.7) b0.001 0.496
Insulinogenic Index 0.7 (0–2.6) 0.9 (0.1–4.0) 1.4 (0.3–4.0) 0.112 0.878
Fasting C-peptide (ng/ml) 1.3 ± 0.6 1.7 ± 0.6 1.8 ± 0.6 0.002 0.457
AUCCpep (ng/ml) 436 ± 231 521 ± 211 604 ± 213 b0.001 0.067
Insulin sensitivity indexes
Homa-IR 0.53 (0.03–2.69) 1.7 (0–5.8) 2.2 (0–6.3) b0.001 1
QUICKI 0.45 ± 0.10 0.37 ± 0.08 0.36 ± 0.08 0.003 0.621
ISI-Matsuda 14.5 (2.0–34.7) 5.7 (2.1–30.9) 5.1 (2.7–39.9) b0.001 0.959
AUC: area under the curve; OGTT: oral glucose tolerance test; GST: glucagon stimulation test.
AUCINS: AUC of insulin during OGTT; AUCCpep: AUC of C-peptide during GST.
p = difference between baseline and 12 months.
p* = difference between 12 and 24 months.
Table 4
Independent variables inﬂuencing the insulin secretion indexes at multivariate analysis
(multiple linear regression). Data are considered as standard deviation score (SDS) values.
Independent variables Dependent variable: Fasting C-peptide
Baseline 12 months
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all other insulin secretion indexes (Table 4; Fig. 1A and B).
After 12 months of therapy a signiﬁcant increase in Homa-β [28.8
(1.6–76.6) vs. 9.7 (2.5–49.1); p b 0.001], fasting C-peptide (1.7 ± 0.6
vs. 1.3 ± 0.6 ng/ml; p = 0.002) and AUCCpep during GST (521 ± 211
vs. 436 ± 231 ng/ml; p b 0.001) was found, without signiﬁcant change
in insulinogenic index and AUCINS. These trends were maintained after
24 months of treatment, although not statistically signiﬁcant (Table 2).Table 3
Correlation (univariate analysis) among the insulin-secretion indexes and the clinical and
hormonal parameters of GHD children at baseline and after 12 months of GH treatment.
Data are considered as standard deviation score (SDS) values.
Independent variables Dependent variable: Fasting C-peptide
Baseline 12 months
r p r p
Height (SDS) 0.374 b0.001 0.418 0.030
BMI (SDS) 0.484 b0.001 0.485 b0.001
WC (SDS) 0.391 b0.001 0.606 b0.001
IGF-I (SDS) 0.251 0.007 0.778 b0.001
AUCCpep
Height (SDS) 0.476 b0.001 0.423 0.028
BMI (SDS) 0.593 b0.001 0.467 0.001
WC (SDS) 0.458 b0.001 0.565 b0.001
IGF-I (SDS) 0.393 b0.001 0.862 b0.001
Fasting insulin
Height (SDS) 0.325 0.001 0.128 0.534
BMI (SDS) 0.519 b0.001 0.336 0.016
WC (SDS) 0.551 b0.001 0.361 0.007
IGF-I (SDS) 0.216 0.027 0.420 0.004
AUCINS
Height (SDS) 0.239 0.014 0.259 0.257
BMI (SDS) 0.509 b0.001 0.375 0.017
WC (SDS) 0.531 b0.001 0.336 0.055
IGF-I (SDS) 0.232 0.019 0.151 0.394
Β SE p Β SE p
Height (SDS) 0.017 0.064 0.887 0.121 0.130 481
BMI (SDS) 0.445 0.039 0.070 −0.287 0.051 0.349
WC (SDS) −0.034 0.109 0.109 0.215 0.990 0.566
IGF-I (SDS) 0.307 0.001 0.016 0.783 0.001 0.001
AUCCpep
Height (SDS) 0.201 2.880 0.072 0.074 2.906 0.467
BMI (SDS) 0.434 1.741 0.058 −0.088 1.113 0.625
WC (SDS) −0.596 5.150 0.252 0.348 7.608 0.300
IGF-I (SDS) 0.379 0.293 0.002 0.880 0.127 b0.001
Fasting insulin
Height (SDS) 0.139 0.370 0.199 – – –
BMI (SDS) 0.111 0.230 0.614 −0.317 0.707 0.441
WC (SDS) 0.299 2.188 0.304 0.433 2.410 0.247
IGF-I (SDS) 0.081 0.004 0.477 0.320 0.007 0.130
AUCINS
Height (SDS) −0.007 3.634 0.956 – – –
BMI (SDS) 0.272 1.770 0.291 0.375 1.500 0.117
WC (SDS) 0.088 0.415 0.680 – – –
IGF-I (SDS) 0.104 2.954 0.436 – – –
Homa-β
Height (SDS) 0.166 1.610 0.114 – – –
BMI (SDS) 0.081 0.999 0.704 0.114 1.094 0.522
WC (SDS) 0.260 2.971 0.205 – – –
IGF-I (SDS) 0.083 0.016 0.448 0.346 0.025 0.058
Insulinogenic index
Height (SDS) – – – – – –
BMI (SDS) – – – – – –
WC (SDS) – – – 0.449 0.156 0.105
IGF-I (SDS) – – – – – –
Fig. 1. Independent correlation at multivariate analysis (multiple linear regression) between IGF-1 SDS and fasting C-peptide (A) and AUCCpep (B) at baseline and between IGF-1SDS and
fasting C-peptide (C) and AUCCpep (D) after 12 months of GH therapy.
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both fasting C-peptide and AUCCpep with IGF-I SDS (both p b 0.001),
height SDS (p = 0.030 and p = 0.028, respectively), BMI SDS
(p b 0.001 and p = 0.001, respectively) and WC SDS (both p b 0.001)
was found. We found that fasting insulin signiﬁcantly correlated with
IGF-I SDS (p = 0.004), BMI SDS (p = 0.016) and WC SDS (p = 0.007),
Homa-β correlated with IGF-I SDS (p = 0.005) and BMI SDS (p =
0.030), AUCINS correlated with BMI SDS (p = 0.017) and insulinogenic
index correlated with WC SDS (p = 0.001) (Table 3). At multivariate
analysis, both fasting C-peptide (beta 0.783, p = 0.001) and AUCCpep
(beta 0.880, p b 0.001) independently correlated with IGF-I SDS, while
no signiﬁcant correlation was found for the other insulin secretion in-
dexes (Table 4; Fig. 1C and D).). These data have not been conﬁrmed
at 24 months of treatment (data not shown).
As additional analysis, we grouped all GHD children according to
gender and family history of diabetes and we did not found any differ-
ence in all metabolic parameters between males and females and be-
tween children with or without family history of diabetes (data not
shown).
4. Discussion
The mutual relationship between insulin-secretion and GH/IGF-I
axis is well known in healthy subjects, as well as in diabetic patients
[16,17]. Given the insulin antagonist action of GH, in addition to the di-
rect stimulatory effect on β-cell, GHT can lead to glucose metabolism
impairment through decreased insulin sensitivity and impaired pancre-
atic β-cell function [12]. Therefore, a reliable evaluation of the insulinsecretion inGHDchildren duringGHT is very important. In this prospec-
tive study we demonstrated the greater reliability of C-peptide than in-
sulin levels as an estimate of insulin secretion in children with GHD,
both at baseline and during the ﬁrst 12 months of GHT. Indeed, we
showed the limitation of the insulin-derived indexes of insulin secretion
because of their lack of correlationwith the parameters used in the clin-
ical practice tomonitor GHT. The effect of GHT on glucosemetabolism is
predominantly insulin antagonistic. A marked hyperinsulinemia and a
resistance to the action of insulin, as demonstrated by euglycemic
clamp studies in healthy subjects, have been demonstrated [7,32]. We
already demonstrated an increase in HOMA-IR, related to the increased
insulin levels and without any untoward effect on glucose metabolism,
in a small group of GHD children after GHT [33]. A subtle form of insulin
resistance, deﬁned as a diminished biological response to a given insulin
concentration, can be assumed as the mechanism by which basal glu-
cose turnover did not change after GHT despite the increase in insulin
levels. Indeed, if the sensitivity to insulin was maintained, a reduction
in glucose levels should occur. We showed a signiﬁcant increase in
fasting glucose levels despite the concomitant increase in insulin during
GHT, suggesting the inability of the β-cells to adequately compensate
the insulin resistance state. However, in this study, only fasting glucose
showed a signiﬁcant increase, although it remained within the limits of
normality, while no signiﬁcant change was found in AUCGLU and HbA1c
levels, and these data could explain the maintenance of normal glucose
tolerance during GHT. Similarly, in adult GHDpatients GHT seems to re-
sult in a signiﬁcant increase in both insulin and C-peptide levels, but in-
sufﬁcient tomatch the change in insulin sensitivity, as demonstrated by
the trend to increase in stimulated glucose levels [19,34].
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insulin sensitivity, evaluated using the gold standard euglycemic
hyperinsulinemic clamp method, and a concomitant inadequate β-cell
compensation to the decreased insulin sensitivity [6], but a limit of
these evaluations was the use of insulin secretion indexes derived
from insulin levels [35–37].
It is well known that β-cell function cannot be accurately estimated
on the basis of the endogenous insulin levels because of the pulsatile re-
lease pattern and the short half-life and a more accurate estimation
could be provided by C-peptide, a byproduct of insulin production
with a half-life of 30 min. Since insulin and C-peptide are cosecreted
by β-cells on an equimolar basis, the stimulated secretion of C-peptide
is widely accepted as a measure of β-cell function [38–40]. Some au-
thors have also demonstrated a stronger correlation among OGTT and
the gold standard insulin secretion method (hyperglycemic clamp) for
C-peptide than for insulin, probably related to the difference in C-pep-
tide kinetics and insulin clearance [41,42]. For these reasons, the use
of the insulin concentration as an index of insulin secretion during
GHT might be misleading, although very few studies evaluated the C-
peptide levels in GHDchildren.Using thehyperglycemic clampHeptulla
et al. have demonstrated a signiﬁcant increase in both the ﬁrst and sec-
ond phase insulin and C-peptide response in short children after GHT
[18]. In our study, the consistent elevation in plasma insulin (and conse-
quently in Homa-β index) and C-peptide levels in the fasting state and
their responses to the stimulation by OGTT or glucagon indicates that
insulin synthesis and secretion were increased by GHT, which may be
due to the insulin sensitivity reduction, as demonstrated by the increase
in Homa-IR and the decrease in QUICKI and ISIMatsuda, aswell as to the
direct insulinotropic effect of GH on the β-cells. Indeed, in vitro studies
of rat pancreatic cells have demonstrated that GHdirectly acts onβ-cells
to stimulate both expression of the insulin gene and DNA synthesis and
cell replication independently of the plasma glucose concentration [9,
10]. Our ﬁndings are supported by the data of Walker et al. who has
shown a consistent increase both in insulin and C-peptide concentra-
tions in prepubertal children after 12 months of GHT. However, these
authors did not evaluate any correlation among clinical, hormonal and
metabolic parameters [22].
In the current study we found that, among all indexes of insulin se-
cretion evaluated, only C-peptide levels, especially those stimulated
after GST, correlate with IGF-I both after 12 months of GHT and also at
baseline. Indeed, in untreated GHD with lower IGF-I concentrations
we found lower C-peptide levels compared with control subjects,
whereas insulin levels and the other indexes of insulin secretion were
similar. A decrease in hepatic clearance of insulin duringGHT can be hy-
pothesized in determining a greater peripheral hyperinsulinemia.
Therefore, measuring C-peptide may override problems associated
with the difference in insulin clearance and its effect on circulating insu-
lin levels and it may bemore informative than insulin levels in the eval-
uation of the insulin secretion [21]. In addition, the strong correlation
between C-peptide and IGF-I levels leads us to consider C-peptide a
very reliable marker during GHT. These ﬁndings strongly support that
insulin secretion is a major co-regulator of IGF-I levels also in GHD chil-
dren and they are consistent with other studies that have reported a
correlation between C-peptide and IGF-I levels [16,17].
A limit of this study is represented by the lack of data of the control
group during the follow-up,mainly due to ethical reasons in submitting
these healthy children to GST once a year. Indeed, we cannot rule out
with certainty that these results are due to some other factor, in addition
to the GHT. Even if all children were prepubertal, a minimal role played
by the change of gonadal hormones during the follow-up cannot be
ruled out, although nobody changed its pubertal stage at visual inspec-
tion, no difference was found between males and females and although
the statistical differences in auxological andmetabolic parameters were
corrected for age and pubertal status.
In conclusion, a relationship between insulin-secretion and IGF-I
levels is documented in GHD children both at baseline and duringGHT and C-peptide has proven to be the most reliable indicator of insu-
lin secretion correlated to IGF-I levels. Therefore, we suggest the use of
GST not only as a diagnostic test for the GH assessment at baseline but
also as a useful tool, instead of OGTT, for the evaluation of insulin secre-
tion during GHT in children, at least during the ﬁrst year, to simplify the
test in clinical practice and to reduce costs and resources. Additional
larger case-control studies with longer follow-up will validate these
results.
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